<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>依替膦酸钠 &#8211; 元哲咨询</title>
	<atom:link href="https://www.yuanzhezixun.com/tag/yitilinsuanna/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.yuanzhezixun.com</link>
	<description>行业研究专家</description>
	<lastBuildDate>Thu, 25 May 2023 06:15:47 +0000</lastBuildDate>
	<language>zh-Hans</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	

<image>
	<url>https://www.yuanzhezixun.com/wp-content/uploads/2021/10/cropped-shcrilogo-c-45x45.jpg</url>
	<title>依替膦酸钠 &#8211; 元哲咨询</title>
	<link>https://www.yuanzhezixun.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>2021-2025年中国唑来膦酸市场研究报告：中国市场仿制药销售额已经超过原研药</title>
		<link>https://www.yuanzhezixun.com/chinas-zoledronic-acid-market-report/</link>
		
		<dc:creator><![CDATA[Timlee]]></dc:creator>
		<pubDate>Thu, 02 Sep 2021 07:01:08 +0000</pubDate>
				<category><![CDATA[医/药/保健]]></category>
		<category><![CDATA[报告速递]]></category>
		<category><![CDATA[行业资讯]]></category>
		<category><![CDATA[Fresenius Kabi]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[ZOMETA]]></category>
		<category><![CDATA[伊班膦酸钠]]></category>
		<category><![CDATA[依替膦酸钠]]></category>
		<category><![CDATA[利塞膦酸钠]]></category>
		<category><![CDATA[双膦酸盐]]></category>
		<category><![CDATA[唑来膦酸]]></category>
		<category><![CDATA[唑来膦酸区域分析]]></category>
		<category><![CDATA[唑来膦酸市场份额]]></category>
		<category><![CDATA[唑来膦酸市场竞争]]></category>
		<category><![CDATA[唑来膦酸市场细分]]></category>
		<category><![CDATA[唑来膦酸市场规模]]></category>
		<category><![CDATA[天晴依泰]]></category>
		<category><![CDATA[密固达]]></category>
		<category><![CDATA[密迪]]></category>
		<category><![CDATA[帕米膦酸钠]]></category>
		<category><![CDATA[恒瑞医药]]></category>
		<category><![CDATA[正大天晴]]></category>
		<category><![CDATA[氯膦酸二钠]]></category>
		<category><![CDATA[海蓉药业]]></category>
		<category><![CDATA[艾朗]]></category>
		<category><![CDATA[英卡膦酸钠]]></category>
		<category><![CDATA[诺华]]></category>
		<category><![CDATA[费森尤斯卡比]]></category>
		<category><![CDATA[阿仑膦酸钠]]></category>
		<category><![CDATA[骨质疏松症]]></category>
		<category><![CDATA[骨质疏松骨折]]></category>
		<guid isPermaLink="false">http://www.yuanzhezixun.com/?p=26839</guid>

					<description><![CDATA[唑来膦酸是第三代双膦酸盐，用于治疗骨质疏松。据CRI元哲市场调研，2020年，由于COVID-19疫情的影响，中国市场唑来膦酸销售额下降到约5.07亿元人民币（7800万美元），2016-2020年CAGR约-3.9%。CRI元哲预计随着COVID-19在中国得到有效控制，2021-2025年中国唑来膦酸市场将呈现恢复性增长。<div class='yarpp yarpp-related yarpp-related-rss yarpp-related-none yarpp-template-list'>

没有相关文章
</div>
]]></description>
		
		
		
			</item>
	</channel>
</rss>
